Table 1 Cohort baseline at menopause diagnosis according to use or non-use of hormone
Characteristics | Oestrogen Users N = 7678) | Tibolone Users N = 1539 | Combined Hormone users N = 9137 | Progestogen Users N = 3747 | Non-users N = 29081 (%) | |
|---|---|---|---|---|---|---|
Age (y) | 40 to 49 | 2987 (39%) | 275 (18%) | 3941 (43%) | 2212 (59%) | 9795 (34%) |
50 to 59 | 3229 (42%) | 902 (59%) | 4464 (49%) | 1348 (36%) | 13189 (45%) | |
60 to 70 | 1462 (19%) | 362 (24%) | 732 (8%) | 187 (5%) | 6097 (21%) | |
Mean (SD) | 52.6 (7.23) | 55.1 (6.16) | 50.9 (5.54) | 49.1 (5.44) | 53.4 (7.24) | |
Alcohol user 1 | Non-user | 583 (16%) | 104 (14%) | 617 (14%) | 279 (16%) | 2243 (17%) |
User | 3097 (83%) | 615 (85%) | 3840 (85%) | 1437 (83%) | 10386 (81%) | |
Ex-user | 69 (2%) | 7 (1%) | 57 (1%) | 20 (1%) | 197 (2%) | |
Smoker 2 | Non-user | 2526 (53%) | 501 (54%) | 2966 (52%) | 1208 (54%) | 9719 (59%) |
User | 1452 (30%) | 279 (30%) | 1817 (32%) | 720 (32%) | 4010 (24%) | |
Ex-user | 800 (17%) | 149 (16%) | 955 (17%) | 317 (14%) | 2766 (17%) | |
BMI 3 | Underweight | 76 (2%) | 13 (1%) | 86 (2%) | 24 (1%) | 222 (1%) |
Normal | 1928 (41%) | 374 (40%) | 2524 (44%) | 833 (39%) | 5771 (37%) | |
Overweight | 1606 (34%) | 338 (36%) | 1943 (34%) | 627 (30%) | 5038 (32%) | |
Obese | 1004 (21%) | 194 (21%) | 1034 (18%) | 530 (25%) | 3812 (25%) | |
Morbidly Obese | 121 (3%) | 25 (3%) | 122 (2%) | 104 (5%) | 702 (5%) | |
Mean (SD) | 26.9 (5.47) | 27.1 (5.80) | 26.4 (5.17) | 27.7 (6.39) | 27.7 (6.11) | |
Practice IMD 4 | 0 | 1759 (23%) | 311 (20%) | 1988 (22%) | 832 (22%) | 6112 (21%) |
1 | 1252 (16%) | 248 (16%) | 1609 (18%) | 702 (19%) | 5287 (16%) | |
2 | 1578 (21%) | 255 (17%) | 1804 (20%) | 764 (20%) | 5743 (20%) | |
3 | 1453 (19%) | 344 (22%) | 1751 (19%) | 731 (20%) | 5757 (20%) | |
4 | 1636 (21%) | 381 (25%) | 1985 (22%) | 718 (19%) | 6182 (21%) | |
Hysterectomy | 3470 (45%) | 165 (11%) | 462 (5%) | 472 (13%) | 3229 (11%) | |
NSAID use | 4191 (55%) | 879 (57%) | 4750 (52%) | 2242 (60%) | 13993 (48%) | |
Bisphophonates | 188 (2%) | 57 (4%) | 192 (2%) | 53 (2%) | 827 (3%) | |
Calcium supplements | 419 (5%) | 118 (8%) | 477 (5%) | 113 (3%) | 1707 (6%) | |
GORD symptoms 5 | 1915 (25%) | 387 (25%) | 2031 (22%) | 859 (23%) | 6689 (23%) | |
PPI use 5 | 564 (7%) | 88 (6%) | 555 (6%) | 239 (6%) | 1947 (7%) | |